secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001628280-24-035864
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn reports Q2 net loss $23M; cash $285M into 2027; FHD-286 AML data Q4; FHD-909 first patient H2 2024
--------------------------------------------------------------------------------

- Net loss $23.0M for Q2 2024 vs $29.5M in Q2 2023; collaboration revenue $6.9M.
- Cash, equivalents & marketable securities $285.2M as of June 30, 2024; expected cash runway into 2027.
- Topline Phase 1 data for FHD-286 + decitabine in r/r AML anticipated Q4 2024; includes safety, efficacy, PK/PD.
- FHD-909 (SMARCA2 selective inhibitor) IND cleared May 2024; first patient dosing H2 2024 in SMARCA4 mutated NSCLC.
- Selective CBP degrader IND-enabling studies on track to start Q4 2024; $110M financing closed May 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024035864/0001628280-24-035864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024035864/fhtx-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer